Arexis AB has today initiated a phase II clinical study in the area of lipid metabolism

Arexis AB has today initiated a phase II clinical study in the area of lipid metabolism. The study will be completed before the end of this year. Further details will be released shortly. Arexis AB is a drug discovery and development company, pioneering the use of genetics in highly selected disease models to pinpoint specific genes involved in multifactorial metabolic and inflammatory diseases. Founded in 1999, Arexis is dedicated to addressing unmet medical needs and delivering improved therapies based on effective and selective new drugs. The head office is in Gothenburg. For more information please contact: Björn Löwenadler, CSO, Arexis AB +46 706 31 00 30 Bjorn.lowenadler@arexis.com www.arexis.com ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/07/08/20030708BIT00460/wkr0001.doc http://www.waymaker.net/bitonline/2003/07/08/20030708BIT00460/wkr0002.pdf